Overview
Oculis Holding AG is a biopharmaceutical company based in Switzerland, primarily engaged in the development of treatments for ophthalmic diseases. With a strong focus on innovation in ocular therapies, the company aims to address the unmet needs of patients suffering from eye conditions. Among its notable projects, Oculis is pioneering technologies to enhance the delivery of drugs directly to the eye, potentially offering non-invasive alternatives to current treatments that often require injections. Key areas of their research include therapies for diabetic macular edema and other severe eye diseases, positioning them at the forefront of ocular therapeutic development in the biopharmaceutical industry.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Oculis Holding AG as of June 30, 2025 is 0.76 MM.
- The operating income for Oculis Holding AG as of June 30, 2025 is -76.13 MM.
- The net income for Oculis Holding AG as of June 30, 2025 is -107.43 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 0.76 | -76.13 | -107.43 |
| 2025-03-31 | 0.75 | -77.85 | -102.90 |
| 2024-12-31 | 0.69 | -73.20 | -85.78 |
| 2024-09-30 | 0.87 | -68.13 | -69.62 |
| 2024-06-30 | 0.87 | -62.96 | -66.84 |
| 2024-03-31 | 0.88 | -51.22 | -58.88 |
| 2023-12-31 | 0.88 | -45.85 | -88.80 |
| 2023-09-30 | 0.91 | -44.78 | -85.49 |
| 2023-06-30 | 0.90 | -38.69 | -78.03 |
| 2023-03-31 | 0.89 | -35.14 | -74.93 |
| 2022-12-31 | 0.91 | -32.38 | -38.70 |
| 2022-09-30 | 1.08 | -25.95 | -35.06 |
| 2021-12-31 | 0.96 | -13.23 | -18.55 |
| 2020-12-31 | 0.99 | -12.34 | -14.87 |
Income Statement: EPS
- The earnings per share basic for Oculis Holding AG as of June 30, 2025 is -2.31.
- The earnings per share diluted for Oculis Holding AG as of June 30, 2025 is -2.31.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | -2.31 | -2.31 |
| 2025-03-31 | -2.38 | -2.38 |
| 2024-12-31 | -2.12 | |
| 2024-09-30 | -1.79 | -1.79 |
| 2024-06-30 | -1.78 | -1.78 |
| 2024-03-31 | -1.64 | -1.64 |
| 2023-12-31 | -2.97 | |
| 2023-09-30 | -3.95 | -3.95 |
| 2023-06-30 | -5.83 | -5.83 |
| 2023-03-31 | -12.92 | -12.92 |
| 2022-12-31 | -11.32 | |
| 2022-09-30 | -10.80 | -10.80 |
| 2021-12-31 | -5.84 | |
| 2020-12-31 | -5.77 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Oculis Holding AG as of June 30, 2025 is -56.24 MM.
- The cash from investing activities for Oculis Holding AG as of June 30, 2025 is -23.45 MM.
- The cash from financing activities for Oculis Holding AG as of June 30, 2025 is 106.45 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -56.24 | -23.45 | 106.45 |
| 2025-03-31 | -52.74 | -67.55 | 157.69 |
| 2024-12-31 | -47.50 | -17.56 | 54.03 |
| 2024-09-30 | -50.91 | 6.04 | 51.76 |
| 2024-06-30 | -52.46 | -1.94 | 52.94 |
| 2024-03-31 | -51.95 | -55.72 | 34.57 |
| 2023-12-31 | -53.84 | -54.21 | 129.67 |
| 2023-09-30 | -47.36 | -77.43 | 128.93 |
| 2023-06-30 | -42.31 | -74.13 | 130.43 |
| 2023-03-31 | -34.89 | -2.79 | 96.97 |
| 2022-12-31 | -25.07 | -3.55 | 1.71 |
| 2022-09-30 | -21.93 | -2.05 | 5.51 |
| 2021-12-31 | -13.82 | -0.03 | 55.19 |
| 2020-12-31 | -12.03 | -0.02 | 4.86 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2021-12-31 | |||
| 2020-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2021-12-31 | ||
| 2020-12-31 |
Management Effectiveness
- The roa for Oculis Holding AG as of June 30, 2025 is -0.74.
- The roe for Oculis Holding AG as of June 30, 2025 is -0.91.
- The roic for Oculis Holding AG as of June 30, 2025 is -0.63.
- The croic for Oculis Holding AG as of June 30, 2025 is 0.22.
- The ocroic for Oculis Holding AG as of June 30, 2025 is -0.32.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | -0.74 | -0.91 | -0.63 | 0.22 | -0.32 |
| 2025-03-31 | -0.87 | -1.09 | -1.15 | -0.14 | -0.64 |
| 2024-12-31 | -0.61 | -0.74 | -0.72 | 0.05 | -0.52 |
| 2024-09-30 | -0.52 | -0.63 | -0.59 | 0.02 | -0.45 |
| 2024-06-30 | -1.59 | -0.74 | -0.91 | -0.65 | |
| 2024-03-31 | -2.40 | -0.94 | 0.20 | -0.57 | |
| 2023-12-31 | -1.94 | -0.80 | 0.02 | -0.45 | |
| 2023-09-30 | -0.66 | 0.07 | -0.36 | ||
| 2023-06-30 | -0.67 | -0.32 | 0.03 | -0.18 | |
| 2023-03-31 | -0.67 | -2.33 | -0.37 | -1.34 | |
| 2022-12-31 | -0.96 | -0.47 | -0.60 | ||
| 2022-09-30 | -0.96 | -0.47 | -0.60 | ||
| 2021-12-31 | -0.35 | 0.78 | -0.26 | ||
| 2020-12-31 |
Gross Margins
- The gross margin for Oculis Holding AG as of June 30, 2025 is -73.76.
- The net margin for Oculis Holding AG as of June 30, 2025 is -137.38.
- The operating margin for Oculis Holding AG as of June 30, 2025 is -103.94.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | -73.76 | -137.38 | -103.94 |
| 2025-03-31 | -74.92 | -125.04 | -106.71 |
| 2024-12-31 | -54.70 | -80.21 | -78.49 |
| 2024-09-30 | -49.77 | -76.74 | -72.28 |
| 2024-06-30 | -37.76 | -67.21 | -58.47 |
| 2024-03-31 | -32.12 | -100.57 | -51.93 |
| 2023-12-31 | -29.82 | -93.73 | -49.10 |
| 2023-09-30 | -25.62 | -87.18 | -43.23 |
| 2023-06-30 | -23.37 | -87.18 | -43.23 |
| 2023-03-31 | -23.37 | -64.60 | -39.33 |
| 2022-12-31 | -16.39 | -32.32 | -23.91 |
| 2022-09-30 | -16.39 | -32.32 | -23.91 |
| 2021-12-31 | -8.97 | -19.32 | -13.78 |
| 2020-12-31 | -8.40 | -14.98 | -12.42 |
Identifiers and Descriptors
| Central Index Key (CIK) | 1953530 |
Industry Groups
| SIC 2834 - Pharmaceutical Preparations |
